2299 results about "Extracellular vesicle" patented technology

The invention relates to method and kits for highly specific isolation of extracellular vesicles (EVs) by targeting at least two EV surface markers. The invention further relates to methods and kits for analyzing EVs and their contents.

The invention discloses a blood extracellular vesicle miRNA (micro Ribonucleic Acid), miRNAs (micro Ribonucleic Acid) hsa-miR-150-3p, hsa-miR-150-5p, hsa-miR-335-3p, hsa-miR-375, hsa-miR-4433b-5p and hsa-miR-4732-5p, which can be used as biomarkers for early diagnosis of lung cancer, so that the blood extracellular vesicle miRNA can be used for preparing a chip, a detection reagent or a detection kit for early diagnosis of lung cancer. The blood extracellular vesicle miRNA biomarker disclosed by the invention has high sensitivity and high specificity on early diagnosis of lung cancer, so that false positive caused by a traditional diagnosis method can be reduced, and the miRNA biomarker has a potential good clinical application value.

The invention discloses a method for extracting extracellular vesicles from dried Sanguisorba officinalis rhizomes and application of the extracellular vesicles, and relates to the technical field of molecular biology and biomedicine.The method comprises the following steps that S1, rehydration is conducted, specifically, the dried Sanguisorba officinalis rhizomes are subjected to liquid nitrogen quick freezing and then ground into powder at the low temperature, the powder and hydration liquid are mixed according to the proportion of 1: 10 (w / v), the mixture is slowly stirred for 2-4 h at the temperature of 4 DEG C, and the extracellular vesicles are obtained; removing large-particle impurities by using sterile gauze or a filter screen, and collecting filtrate; according to the method, through the synergistic effect of multiple enzymolysis and in combination with cellulase, pectinase and the like, the degradation efficiency is remarkably improved, meanwhile, EDTA is chelated with metal ions, and the enzymolysis effect is enhanced. Short-time alternating ultraviolet light is introduced to activate'dormant 'vesicles, so that the yield and the biological activity are improved. Secondly, multiple protection mechanisms, such as vitamin C, EDTA (Ethylene Diamine Tetraacetic Acid), cane sugar, BSA (Bovine Serum Albumin) and an ultraviolet protective agent are adopted, so that the integrity and the biological activity of the vesicles are ensured.

The invention relates to compositions (e.g., pharmaceutical compositions), uses, methods, non-therapeutic and therapeutic methods related to senolytic agents encapsulated or comprised in Muse cell derived extracellular vesicles (e.g. exosomes). Such compositions and methods are useful for specifically killing senescent cells and reverting any symptoms, disorders or diseases associated with senescence.

The invention relates to a drug delivery carrier based on extracellular vesicles and application thereof.The drug delivery carrier contains extracellular vesicle scaffold protein and recombinant membrane fusion protein, the recombinant membrane fusion protein comprises a first fragment and a second fragment, the amino acid sequence of the first fragment is shown as SEQ ID NO: 5, and the amino acid sequence of the second fragment is shown as SEQ ID NO: 6; the second fragment has n amino acids, the sequence of the second fragment is the sequence of the first n amino acids at the N end of the amino acid sequence as shown in SEQ ID NO: 7, and n is an integer between 50 and 200. According to the drug delivery carrier disclosed by the invention, the efficiency of releasing drug active molecules before reaching lysosome is remarkably improved, and the drug effect of extracellular vesicle drugs can be improved.

Long COVID or Post Acute Sequelae of COVID-19 (PASC), is a prolonged, debilitating syndrome that follows acute SARS-CoV-2 infection in >10% of cases. Human bone marrow mesenchymal stem cell derived extracellular vesicles (hBM-MSC EVs) can present a new therapeutic option.

The invention provides a traditional Chinese medicine meridian prescription system based on multi-omics integration analysis of extracellular vesicles, and the system comprises a data collection module which is used for collecting biopsy sample information of different groups of individuals based on related experiments and literatures of traditional Chinese medicine meridian prescription treatment; the data processing module is used for obtaining and preprocessing extracellular vesicle data and intestinal flora data based on biopsy sample information; the multi-omics integration module is used for obtaining multi-omics integration data; the discovery and verification module is used for obtaining the potential menstrual prescription drug effect evaluation biomarker and performing experimental verification on the potential menstrual prescription drug effect evaluation biomarker to obtain a verification result; and the system biology application module is used for obtaining a regulatory mechanism of the extracellular vesicles in a biological system based on construction of a gene-protein-metabolite interaction network. The invention can comprehensively reveal the pharmacodynamic mechanism of the traditional Chinese medicine menstrual prescription, and provides strong technical support and application prospect for the modern, scientific and internationalized development of traditional Chinese medicines.

The embodiment of the invention discloses a method for extracting extracellular vesicles from a traditional Chinese medicine dry product. The method comprises the following steps: taking a dry traditional Chinese medicine product as a raw material, and sequentially performing crushing, soaking, first-order enzymolysis, wall breaking, differential centrifugation, second-order enzymolysis, high-speed centrifugation, ultracentrifugation and ultrafiltration enrichment to obtain the extracellular vesicles. A two-step enzymolysis method is adopted in the enzymolysis process, impurities are removed to the maximum extent in a sequence difference enzymolysis mode, and the structure and function stability of the exosome are protected. According to the invention, the differential centrifugation and the enzymolysis method are alternately used, so that impurities with different sizes and different properties can be removed more thoroughly. According to the method, the cost is strictly controlled, the exosome purification efficiency is relatively high, the concentration of the obtained dry exosome is relatively high, and the operability is extremely high.

Disclosed are methods of treating radiation-induced skin damage comprising administering extracellular vesicle and protein compositions.

Disclosed are methods of treating traumatic brain injury in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

Methods of treating lumbar facet joint syndrome by administering extracellular vesicle and protein compositions.

The invention provides a drug-loaded callicarpa nudiflora-derived extracellular vesicle as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations. The drug-loaded callicarpa nudiflora-derived extracellular vesicle has relatively high encapsulation efficiency and drug loading rate and good gastrointestinal tract stability and biocompatibility, can target a colitis disease part to reduce adverse reaction of a drug and improve the curative effect, solves the problem that the drug is insoluble in water, and can be used for preparing the drug-loaded callicarpa nudiflora-derived extracellular vesicle. The invention provides a novel drug delivery strategy for treating the ulcerative colitis, and is expected to become an effective strategy for clinically treating the ulcerative colitis, thereby achieving the effects of synergistically treating the ulcerative colitis and improving the effectiveness and safety of drug delivery.

Disclosed are methods of treating patients receiving an organ transplant by administering extracellular vesicle composition.

The invention belongs to the technical field of biological agents, and particularly discloses application of lily extracellular vesicles in preparation of tumor treatment drugs. The preparation method of the lily extracellular vesicles comprises the following steps: S1, juicing lily bulb tissues, and filtering to obtain a lily bulb stock solution; s2, treating the lily bulb stock solution obtained in the step S1 to obtain a lily extracellular vesicle extracting solution; s3, concentrating and purifying the lily extracellular vesicle extracting solution obtained in the step S2 to obtain lily extracellular vesicles; wherein in the step S2, the treatment comprises centrifugation and filter membrane filtration. The lily extracellular vesicle provided by the invention can effectively promote polarization of M2-type macrophages to M1-type macrophages, shows remarkable immunoregulation ability, is good in biocompatibility, and has the potential of preparing anti-cancer drugs.

The invention belongs to the technical field of biological medicines, and particularly relates to a sperm injury repair model and an establishment method thereof. Comprising the following steps: step 1, establishing a sperm lead poisoning model; and 2, establishing a lead poisoning sperm repair model. The method for establishing the lead poisoning sperm repair model in the step 2 comprises the following steps: (1) preparing a preparation for optimizing sperm functions in an extracellular vesicle way; (2) repairing the damaged sperms by using the preparation for optimizing the sperm function through the extracellular vesicles; and (3) detecting the activity of the repaired sperms. In the invention, by establishing a sperm injury repair model and adopting an extracellular vesicle modification technology, the key functional protein is introduced into the extracellular vesicle, and the method has important significance on auxiliary researches such as development and research of related drugs for improving sperm injury and improving sperm motility of asthenospermia patients in vitro.

Disclosed are methods of treating infertility or increasing fertility of a female subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

Provided herein are compositions and methods for inducing an immune response in a subject, wherein the compositions comprise apoptotic cells, extracellular vesicles (EVs), and combinations thereof. Various compositions comprising mRNA encoding a microbial antigen are also provided. Further provided herein are compositions engineered to overexpress the human arrestin domain containing protein 1 [ARRDC1].

The invention belongs to the field of biological medicines, and discloses an application of Akkermansia muciniphila or an extracellular vesicle of the Akkermansia muciniphila in preparation of a medicine for alleviating the ischemic necrosis of the alcoholic femoral head. Based on the pathogenesis characteristics of the AIONFH, the Akk bacteria and the extracellular vesicles thereof are used for treating the AIONFH for the first time, the molecular mechanism of the Akk bacteria and the extracellular vesicles thereof for regulating and controlling the intestinal tract-skeleton axis function, inhibiting bone cell apoptosis and improving the bone trabecula microstructure is deeply researched, the anti-pressure ability of bone tissue is improved, and the research blank in the field is filled. Compared with a traditional treatment method, the osteonecrosis pathological change is improved through a single way, and a novel multi-target treatment strategy is provided from multiple aspects of regulating inflammatory response, recovering bone metabolism balance, promoting intraosseous blood supply and the like.

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention discloses application of small extracellular endovesicular protein as a prostatic cancer diagnostic marker, and is characterized in that the small extracellular endovesicular protein is plasma sample sEV protein LAMB1 and / or urine sample sEV protein Histone H4, and the plasma sample sEV protein LAMB1 is applied as a metastatic prostatic cancer diagnostic marker. The sEV protein LAMB1 of the plasma sample is combined with a prostate specific antigen to serve as metastatic prostate cancer; the application of the sEV protein Histone H4 in the urine sample as a prostate cancer grading diagnosis marker, the application of the sEV protein Histone H4 in the urine sample as a high-risk prostate cancer diagnosis marker and the application of the combination of the sEV protein Histone H4 in the urine sample and a prostate specific antigen as the high-risk prostate cancer diagnosis marker have the advantages of high sensitivity and strong specificity.

The invention provides a method for separating extracellular vesicles from a milk source, which comprises the step of adding a dispersing agent before adding a precipitator into the milk source to precipitate casein so as to reduce the wrapping of protein precipitation on the extracellular vesicles and improve the yield of the extracellular vesicles, thereby obtaining a milk source extract rich in the extracellular vesicles.

The invention discloses a typing analysis method for extracellular vesicles secreted by tumor cells and immune cells, which comprises the following steps: designing a PD-L1 protein recognition aptamer PD-L1-L, an EpCAM protein recognition aptamer EpCAM-L and a molecular beacon according to different expression levels of surface markers of the extracellular vesicles (PD-L1 + and EpCAM +) derived from the tumor cells and the extracellular vesicles (PD-L1 + and EpCAM-) derived from the immune cells; when the DNA probe recognizes the extracellular vesicles, fluorescence of the Cy5-PD-L1-L aptamer of the tumor cell source extracellular vesicles is quenched, a fluorescence signal of the Connector is recovered, and the immune cell source extracellular vesicles do not respond, so that the two extracellular vesicles are subjected to typing analysis. The method has the advantages that the extracellular vesicles of different cell sources can be subjected to typing analysis by using a strategy based on double aptamers and double switches, and false positive signals caused by single aptamer recognition are avoided.

The invention belongs to the technical field of stem cell culture and exosome extraction, and provides an RELM beta pre-activated stem cell outer vesicle with high anti-inflammatory and anti-fibrosis activity. According to the method, the mesenchymal stem cells are subjected to hunger culture after being adhered to the wall and then are continuously cultured by a complete culture medium containing RELM beta factors, then supernate is collected, and the exovesicles are obtained through separation. In the preparation process of the extracellular vesicles, the paracrine function of MSC cells is promoted by the RELM beta, the secretion of anti-inflammatory and anti-fibrosis active factors is obviously activated, and the generation of the extracellular vesicles with enhanced anti-inflammatory and anti-fibrosis effects is promoted. Gene modification is not involved, toxic biochemical reagents or materials are not added, exogenous operation steps are simple and convenient, clinical application is guaranteed through sterile operation, no RELM beta residues exist after extracellular vesicle extraction, and the method is safe, non-toxic and effective.

The invention discloses a hydrogel-acellular matrix composite patch containing functionalized extracellular vesicles and a preparation method of the hydrogel-acellular matrix composite patch. The composite patch comprises a hydrogel layer and an acellular pericardium matrix material layer, and an extracellular vesicle-macrophage membrane fusion body (EV-MM) is entrapped in the cross-linked hydrogel. From two aspects of improving the targeting of EVs to the cardiac infarction part and enhancing the retention of the EVs at the cardiac infarction part, the distribution condition of the EVs at the cardiac infarction part is improved, so that the action efficiency of the EVs is improved, and the treatment effect is improved.

A novel Akkermansia muciniphila EB-AMDK39 strain (KCTC 13765BP) and composition containing the novel strain or extracellular vesicles (EVs) derived from the strain are disclosed. The composition can be in a form of pharmaceutical, food, or veterinary composition. The compositions are useful to preventing or treating cancer or inflammatory disease, or ameliorating cancer or inflammatory disease.

The invention discloses a bone joint repairing composition containing stem cell vesicles and application of the bone joint repairing composition, and relates to the technical field of bone joint repairing compositions.The bone joint repairing composition is prepared from, by weight, 90-110 parts of stem cell vesicles and 41-57 parts of thelenota ananas saponin Ananaside A. The stem cell vesicles and the thelenota ananas saponin Ananaside A are combined to form the bone joint repairing composition. The stem cell vesicles are extracellular vesicles derived from human amniotic mesenchymal stem cells. According to the bone joint repairing composition provided by the invention, the stem cell vesicles and the thelenota ananas saponin in a proper proportion are matched for use, so that the synergistic interaction between the stem cell vesicles and the thelenota ananas saponin is realized. Animal experiments show that the composition has a remarkable repairing effect on a rat model with bone and joint injuries, can effectively relieve bone and joint pain symptoms of rats, not only widens the application field of human amniotic mesenchymal stem cell-derived extracellular vesicles, but also provides a new clinical treatment means for bone and joint repairing.

The invention discloses a preparation method of artemisia apiacea extracellular vesicles, which comprises the following steps: step 1, pre-treating artemisia apiacea, carrying out primary centrifugal treatment, removing large plant tissues and cell debris, carrying out secondary centrifugal treatment, filtering by a needle filter, and collecting; step 2, transferring the filtered suspension to a sucrose density gradient solution, then carrying out third centrifugal treatment, collecting the solution with the concentration of 30% in the layer, and carrying out fourth centrifugal treatment to obtain artemisia apiacea extracellular vesicles; the invention further discloses an artemisia apiacea extracellular vesicle, a pharmaceutical composition for treating cerebral apoplexy, a medicine and application of the artemisia apiacea extracellular vesicle in preparation of the medicine for treating cerebral apoplexy. The naturally-sourced vesicle delivery system provided by the invention is expected to have higher safety and lower toxic and side effects, and the enrichment concentration of the therapeutic component at the focus part of cerebral apoplexy is improved, so that the bioavailability and the treatment efficiency of the medicine are remarkably improved.

The present invention provides a method for producing extracellular vesicles, the method including a step for passing a crushed liquid of plants, mushrooms, or microalgae through a depth filter, and a step for subjecting the crushed liquid after passing through the depth filter to ultrafiltration treatment, the depth filter being composed of filaments.

The invention discloses ZIF-8 loaded M2 macrophage outer vesicle hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: inducing M0 macrophages through IL-4 to obtain M2 type macrophages; collecting cell supernate, and separating by adopting an ultracentrifugation method to obtain the M2 type macrophage extracellular vesicle EV; purifying the obtained M2-type macrophage extracellular vesicle EV, mixing the purified M2-type macrophage extracellular vesicle EV with ZIF-8 nanoparticles, and carrying out electroporation treatment to obtain a ZIF-loaded exosome vesicle ZIF (at) EV; performing ultrasonic stirring and mixing on a sodium alginate solution and calcium carbonate, adding the obtained ZIF-coated EV and D-(+)-gluconic acid delta-lactone, and fully stirring and mixing to obtain the product. The ZIF-EV hydrogel disclosed by the invention is effective in wound healing, and the ZIF-EV hydrogel can continuously release the ZIF-EV on the wound to promote wound healing.

The invention discloses a biomarker for auxiliary diagnosis of progressive suprakaryotic paralysis and application thereof, and relates to the technical field of biomedicine. The biomarker is a neuron-derived extracellular vesicle carrying a Tau deformable protein; the Tau deformation protein is 4R Tau or pTau181, and the Tau deformation protein is a protein with the molecular weight of 4R The invention develops a biomarker capable of assisting in diagnosing progressive suprakaryotic paralysis, and the biomarker can be used for effectively identifying a progressive suprakaryotic paralysis (PSP) patient, a Parkinson's disease (PD) patient and a healthy person (HC). Meanwhile, a progressive supranuclear paralysis diagnosis model is also constructed, the sensitivity of the multivariable logistic regression model for distinguishing PSP and HC is 95.7%, the specificity is 90.0%, and the AUC is 0.974; the sensitivity of the multivariable logistic regression model for distinguishing PSP and PD is 96.3%, the specificity is 90.0%, and the AUC is 0.968.